Subtopic Deep Dive
Sibutramine Efficacy and Safety in Obesity Trials
Research Guide
What is Sibutramine Efficacy and Safety in Obesity Trials?
Sibutramine efficacy and safety in obesity trials evaluates the drug's weight loss effects through serotonin and norepinephrine reuptake inhibition against cardiovascular risks in randomized controlled trials.
Sibutramine was assessed in multiple RCTs for short-term weight reduction averaging 4-5 kg over 12 months. Safety concerns, particularly increased heart rate and blood pressure, led to its market withdrawal in 2010. Over 20 clinical trials and reviews, including Lau et al. (2007) with 1158 citations, document these outcomes.
Why It Matters
Trial data on sibutramine shaped pharmacovigilance protocols for anti-obesity drugs, informing FDA and EMA withdrawals due to cardiovascular events (Kang and Park, 2012). It guides current approvals by benchmarking weight loss efficacy (≥5% at 52 weeks) against adverse events like those in Khera et al. (2016, 825 citations). Regulatory decisions on withdrawn agents like sibutramine prevent recurrence in new therapies (Shekelle et al., 2003).
Key Research Challenges
Cardiovascular Risk Assessment
Quantifying sibutramine's blood pressure and heart rate elevations requires meta-analysis of RCTs. Long-term outcomes remain understudied post-withdrawal (Kang and Park, 2012). Khera et al. (2016) highlight inconsistent adverse event reporting across trials.
Long-term Weight Maintenance
Sibutramine achieves initial loss but fails in sustained maintenance without lifestyle intervention (Wadden et al., 2005, 789 citations). Rebound weight gain post-discontinuation complicates efficacy claims. Lau et al. (2007) note pediatric applicability gaps.
Comparative Safety Profiling
Benchmarking sibutramine against orlistat or liraglutide demands standardized adverse event metrics (Khera et al., 2016). Shekelle et al. (2003) reveal similar ephedrine risks, underscoring methodological variances in safety trials.
Essential Papers
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
David C.W. Lau, James D. Douketis, Katherine M. Morrison et al. · 2007 · Canadian Medical Association Journal · 1.2K citations
Obesity is now reaching epidemic proportions in both developed and developing countries and is affecting not only adults but also children and adolescents. Over the last 20 years, obesity has becom...
The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
Thomas A. Wadden, Delia Smith West, Linda M. Delahanty et al. · 2006 · Obesity · 863 citations
Abstract The Look AHEAD (Action for Health in Diabetes) study is a multicenter, randomized controlled trial designed to determine whether intentional weight loss reduces cardiovascular morbidity an...
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
Rohan Khera, M. Hassan Murad, Apoorva K. Chandar et al. · 2016 · JAMA · 825 citations
Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated with achieving at least 5% weight ...
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Thomas A. Wadden, Robert I. Berkowitz, Leslie G. Womble et al. · 2005 · New England Journal of Medicine · 789 citations
The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescrib...
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Arne Astrup, Raffaele Carraro, Nick Finer et al. · 2011 · International Journal of Obesity · 738 citations
Anti-Obesity Drugs: A Review about Their Effects and Safety
Jun Goo Kang, Cheol‐Young Park · 2012 · Diabetes & Metabolism Journal · 581 citations
The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatm...
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Robert H. Eckel, Steven E. Kahn, Ele Ferrannini et al. · 2011 · The Journal of Clinical Endocrinology & Metabolism · 547 citations
Objective: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, intervention...
Reading Guide
Foundational Papers
Start with Lau et al. (2007, 1158 citations) for guidelines context; Wadden et al. (2005, 789 citations) for RCT pharmacotherapy evidence; Kang and Park (2012, 581 citations) for safety synthesis.
Recent Advances
Khera et al. (2016, 825 citations) for comparative meta-analysis; Astrup et al. (2011, 738 citations) contrasts with liraglutide outcomes.
Core Methods
RCTs with ITT analysis for weight/BP endpoints; meta-regression for dose-response; GRADE for evidence quality (Khera et al., 2016; Shekelle et al., 2003).
How PapersFlow Helps You Research Sibutramine Efficacy and Safety in Obesity Trials
Discover & Search
Research Agent uses searchPapers with query 'sibutramine obesity RCT cardiovascular' to retrieve Lau et al. (2007, 1158 citations); citationGraph maps connections to Wadden et al. (2005); findSimilarPapers expands to Kang and Park (2012); exaSearch uncovers trial registries.
Analyze & Verify
Analysis Agent applies readPaperContent on Khera et al. (2016) to extract sibutramine weight loss stats; verifyResponse with CoVe cross-checks cardiovascular claims against Shekelle et al. (2003); runPythonAnalysis meta-analyzes GRADE-graded evidence for blood pressure effects using pandas for RCT data pooling.
Synthesize & Write
Synthesis Agent detects gaps in long-term sibutramine data versus liraglutide (Astrup et al., 2011); Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 20+ refs, latexCompile for report PDF; exportMermaid diagrams cardiovascular risk networks.
Use Cases
"Run meta-analysis on sibutramine RCTs for mean weight loss and BP increase."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas pooling of Wadden et al. 2005 and Khera et al. 2016 data) → forest plot CSV with GRADE scores.
"Draft review section on sibutramine withdrawal citing Lau 2007 and Kang 2012."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → LaTeX PDF with auto-cited bibliography.
"Find code for analyzing obesity trial survival curves like in Look AHEAD."
Research Agent → paperExtractUrls (Wadden et al. 2006) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on Kaplan-Meier scripts adapted for sibutramine data.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ sibutramine papers: searchPapers → citationGraph → readPaperContent → GRADE grading → structured report on efficacy/safety. DeepScan applies 7-step analysis with CoVe checkpoints to verify cardiovascular risks in Lau et al. (2007). Theorizer generates hypotheses on norepinephrine mechanisms from trial contradictions in Kang and Park (2012).
Frequently Asked Questions
What defines sibutramine efficacy in obesity trials?
Efficacy requires ≥5% weight loss at 52 weeks in RCTs, achieved via serotonin/norepinephrine reuptake inhibition (Khera et al., 2016; Wadden et al., 2005).
What methods assessed sibutramine safety?
Safety used meta-analyses of RCTs tracking blood pressure, heart rate, and CV events; Shekelle et al. (2003) methods paralleled ephedrine reviews (Kang and Park, 2012).
What are key papers on sibutramine?
Lau et al. (2007, 1158 citations) guidelines; Wadden et al. (2005, 789 citations) pharmacotherapy trial; Kang and Park (2012, 581 citations) safety review.
What open problems remain?
Post-withdrawal long-term CV data gaps; comparative effectiveness vs. modern GLP-1s; pediatric trial deficits (Lau et al., 2007).
Research Pharmacology and Obesity Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sibutramine Efficacy and Safety in Obesity Trials with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers